30-billion-won Blockbuster “Munmu” Scores 4.7% Viewership Rating on Premiere… Fails to Surpass “The Goryeo-Khitan War”
KBS Epic Historical Drama Returns to TV Screens After Three Years
'Go Geo-jeon' Premieres with Ratings 0.8 Percentage Points Lower Than 5.5%
A 28-episode epic… Starring Lee Hyun-wook, Jang Hyuk, and Kim Kang-woo
[Edaily Reporter YUN GI BACK ] KBS’s epic historical drama “Munmu,” produced with a budget of approximately 30 billion won, debuted with ratings in the 4% range. Poster for the drama “Munmu.” (Photo courtesy of KBS) According to figures released on the 15th by Nielsen Korea, KBS2’s “Munmu,” which premiered the previous day, recorded a viewership rating of 4.7% based on nationwide household ratings. This figure is 0.8 percentage points lower than the 5.5% premiere rating of its predecessor, “The Goryeo-Khitan War,” which aired in 2023. “Munmu” is a historical epic drama that KBS is presenting for the first time in about three years since “The Goryeo-Khitan War,” with a production budget of approximately 30 billion won for the 28-episode series. The drama depicts the process of Silla’s unification of the Three Kingdoms and stars Lee Hyun-wook, Jang Hyuk, Kim Kang-woo, and Park Sung-woong. The premiere depicted the conflict between Kim Chun-chu (played by Kim Kang-woo) and his son Kim Beop-min (played by Lee Hyun-wook), as well as the rebellion led by Yeon Gaesomun (played by Jang Hyuk). Given that “The Goryeo-Khitan War” reached a peak viewership rating of 13.8%, attention is now focused on whether “Munmu” will be able to rebound through word of mouth.
Kim Seong-yeon, Director of Genosco (Photo: E-Daily DB Inc.)
Kim Seong-yeon, a director at Genosco and the largest shareholder of OSCOTEC Inc.(039200), has promised that even if he disposes of his…
HYUNDAIDEPARTMENTSTORECO.,LTD is discontinuing its mobile-exclusive “HYUNDAIDEPARTMENTSTORE FIT Card,” which was launched to attract Gen Z and Millennials, after five years. This decision comes as the…
(Graphic: ChatGPT)
During the second week of November (Nov. 9–13), the domestic pharmaceutical and biotech industry saw significant attention focused on the success of SAMSUNG BIOLOGICS(207940)’s …